Rasmus Holm-Jorgensen

Rasmus Holm-Jorgensen is Chief Financial Officer at Acrivon Therapeutics, Inc. Previously, he was part of the founding team and SVP, Chief Strategy and Portfolio Officer of Kiniksa Pharmaceuticals since its inception in 2015 to April 2022, including through the IPO to the launch of its first product. Prior to Kiniksa, he was Group Vice President and General Manager at Synageva BioPharma, where he created a new business unit with a portfolio of multiple rare disease programs following the company’s IPO in 2011 and culminating in the company’s sale for $9 billion. From 2008 to 2011, Rasmus drove the successful turnaround of the global commercial audiology organization of the GN Group, a global leader in intelligent audio solutions. From 1996 to 2008, Rasmus worked for Novo Nordisk in Denmark, U.S., Brazil and Mexico, where he held positions of increasing responsibility within general management, economy and planning, portfolio analysis, investor relations for North America and finance for LATAM. Rasmus received an M.S. in Economics from the University of Copenhagen and has completed executive training at INSEAD, Stanford University and Harvard Business School.